Overview

Vinorelbine and/or Gemcitabine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of vinorelbine, gemcitabine, or both in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Istituto Nazionale per lo Studio e la Cura dei Tumori
Treatments:
Gemcitabine
Vinblastine
Vinorelbine
Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically proven non-small cell lung cancer
Stage IV OR Stage IIIB that has supraclavicular lymph node metastases or has pleural
deposits and is not curable with surgery or radical radiotherapy No brain metastases
suspected clinically or demonstrated radiologically

PATIENT CHARACTERISTICS: Age: 70 and over Performance status: ECOG 0-2 Life expectancy: Not
specified Hematopoietic: Neutrophil count at least 2000/mm3 Platelet count at least
100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: (Unless caused by tumor) Bilirubin no
greater than 1.25 times upper limit of normal (ULN) SGOT or SGPT no greater than 1.25 times
ULN Renal: Creatinine no greater than 1.5 mg/dL Other: No other serious medical illness No
prior or concurrent malignancy except curatively treated basal cell or squamous cell skin
cancer or carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY: No prior chemotherapy